Price
Target price
€4.87
€4.87
-2.120%
-0.105
-2.120%
-
17.04.24 / Tradegate
WKN: A14QXP / Name: Ose Pharma / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Ose Pharma International S.A. Stock
A loss of -2.120% shows a downward development for Ose Pharma International S.A..
For the coming years our community has positive and negative things to say abot the Ose Pharma International S.A. stock. Criterium "EBIT growth" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Ose Pharma International S.A. in the next few years
Pros
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
News
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical
OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook.
Nicolas Poirier, Chief Executive Officer
OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced